Hanley Jr. Michael Conick 4

What Happened

• Michael Conick Hanley Jr., Chief Operating Officer of Alto Neuroscience (ANRO), was granted a derivative equity award for 131,000 shares on February 11, 2026. The award shows a $0.00 per-share acquisition price (no cash paid at grant).
• This is a grant/award (acquisition) rather than an open-market purchase or sale — typically a retention/compensation grant rather than an immediate market bet.

Key Details

• Transaction type and date: Grant/Award (code A) on 2026-02-11; Form 4 filed 2026-02-13 (appears timely, within the usual two-business-day filing window).
• Amount and price: 131,000 shares, $0.00 per share (derivative award).
• Shares owned after transaction: Not disclosed in the provided filing.
• Vesting: 25% of the shares vest on February 11, 2027; thereafter 1/48th of the shares vest monthly, subject to continuous service (see footnote).
• No indication in the filing of an immediate sale or cashless exercise — this is a grant subject to vesting.

Context

• This is a typical equity compensation grant for an executive and will vest over time (one‑year cliff then monthly vesting), aligning retention incentives with the company. It does not represent an immediate purchase or sale of shares and will only affect outstanding share counts as portions vest or are settled.